Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics Limited recently announced an inadvertent non-compliance with ASX Listing Rule 7.1 due to an oversights regarding the inclusion of milestone shares in its capacity calculation. This led to the company exceeding its placement capacity in October 2025, impacting the validity of certain placement shares for ratification. In response, the company intends to bolster its governance measures, increase awareness among officers, and engage external advisors to ensure full compliance and maintain best practices moving forward.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.05 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a biotechnology company specializing in the development of radiopharmaceutical products for diagnostics and therapy applications, focusing primarily on advancing precision medicine through innovative solutions within the healthcare industry.
Average Trading Volume: 11,532,554
Technical Sentiment Signal: Buy
Current Market Cap: A$102.8M
Learn more about RAD stock on TipRanks’ Stock Analysis page.